Abstract
to compare the efficiency of monotherapy with -blockers vs combined therapy (-blockers in combination with Androgel) in patients with BPH and hypogonadism. a total of 60 men with BPH and hypogonadism, who were randomly selected from outpatient department were included in the study. All patients were divided into 2 groups (n=30). In Group 1 patients received silodosin, while in Group 2 men were prescribed to silodosin plus Androgel 1% topically. The duration of therapy was 6 months. The results of treatment were evaluated during baseline assessment and further visits every 2 months after starting therapy (total 4 time points). according to the ICEF-5 questionnaire, in the Group 2 an improvement in sexual function domain score (from 6.3 to 26.8 points) was shown. In addition, in combination group there were significant changes in PSA level (from 2.25 to 1.8 ng/ml), prostate volume (from 55.1 to 61.3 cm3), residual urine volume (from 72 to 19 ml), urine flow rate (from 13.34 to 21.1 ml/s), waist circumference (from 116 to 103.2 cm) and body mass index (from 35.4 to 27.2 kg/m2), while in monotherapy group none of these indicators significantly improved. the use of topical hormone replacement therapy in combination with -blockers in patients with BPH and concomitant hypogonadism is justified and effective in comparison with monotherapy with -blockers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
